Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Nov 7, 2014; 20(41): 15037-15048
Published online Nov 7, 2014. doi: 10.3748/wjg.v20.i41.15037
Published online Nov 7, 2014. doi: 10.3748/wjg.v20.i41.15037
Immunogenetic biomarkers in inflammatory bowel diseases: Role of the IBD3 region
Manuel Muro, Ruth López-Hernández, Anna Mrowiec, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (Ciberehd), Immunology Service, University Hospital Virgen de la Arrixaca, 30120 Murcia, Spain
Author contributions: Muro M, López-Hernández R and Mrowiec A made substantial contributions to conception and design of the article; Muro M wrote the first draft of the article; López-Hernández R and Mrowiec A revised it critically for important intellectual content; all the authors have approved for publication the final version of the article.
Supported by The Projects from Foundation Seneca, No. 05748/PI/07 and No. 04487/GERM/06; the Fondo de Investigación Sanitaria (FIS) projects CIBERehd, No. PI11/02644 and No. PI11/02686 (in part); the ISCII and Fundación para la Formación e Investigación Sanitarias de la Región de Murcia (FFIS), No. CA11/00034 (to López-Hernández R)
Correspondence to: Manuel Muro, PhD, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (Ciberehd), Immunology Service, University Hospital Virgen de la Arrixaca, Madrid-Cartagena s/n, El Palmar, 30120 Murcia, Spain. manuel.muro@carm.es
Telephone: +34-968-369599 Fax: +34-968-349678
Received: September 20, 2013
Revised: March 1, 2014
Accepted: April 15, 2014
Published online: November 7, 2014
Revised: March 1, 2014
Accepted: April 15, 2014
Published online: November 7, 2014
Core Tip
Core tip: This review gathers information about the importance of IBD3 genomic region in susceptibility to inflammatory bowel disease (IBD). The new and old immunogenetic biomarkers of the IBD3 region (human leukocyte antigen, MHC class I chain-related molecule A, MHC class I chain-related molecule B, and tumor necrosis factor-α and -β) and their role on IBD susceptibility are discussed in the light of recent publications. IBD3 gene polymorphisms and their clinical relevance for the treatment of the IBD patients are also discussed. Insights into the natural history of these complex diseases may allow in the future appropriate patient selection for early aggressive therapy aimed at modifying the course of the disease.